

Korea's HanAll Biopharma invests in American biotech startup Interon

14 February 2023 | News

Interon is developing a new category of immunotherapy for people with neurological and immune disorders starting with autism spectrum disorder

South Korea based HanAll Biopharma is investing in Interon Laboratories, Inc., a US-based biotechnology company focusing on discovering and developing innovative treatments for brain diseases. The investment will fund Interon's continued development of its lead programmes targeting an array of neurological and immune disorders.

Interon is currently focused on developing therapeutics for severe autism spectrum disorder (ASD) by modulating the neuro-immune axis pathway. Interon's technology was pioneered by the scientific co-founders at Harvard Medical School and Massachusetts Institute of Technology (MIT). Using the technology, Interon will proceed with pre-clinical research on developing therapies targeting indications in neurological disorders, starting with ASD.

"We are deeply impressed by the Interon's neuro-immunological approach to treat autism spectrum disorder, and we look forward to further collaborations to make a meaningful contribution to patients," said Sean Jeong, M.D., CEO of HanAll Biopharma.

"Interon is excited to partner with HanAll in our shared goal of developing novel therapeutics to improve human health. We believe HanAll's expertise and history of innovation will help accelerate Interon's lead programs," said Jaspaul Singh, Co-Founder and CEO of Interon Laboratories.